newsfilter
← Latest News
GlobeNewswire·

iTeos Reports First Quarter 2023 Financial Results and Provides Business Updates

– Belrestotug, formerly EOS-448, is advancing through multiple late-stage clinical trials including both doublet and triplet regimens – First-in-class program targeting a new mechanism of action in the adenosine